arrow
S

Simon Bailey

newcastle university
H指数:15
被引数:1,042

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus

罕见儿童中枢神经系统(CNS)肿瘤临床试验交付的战略路线图:一项多利益相关方共识

2026-08-220
OAAI
Quality indicators for the care of children with CNS tumors: An international modified Delphi study

中枢神经系统肿瘤患儿的护理质量指标:一项国际改良德尔菲研究

2026-08-080
OA
Establishing Consensus on the Breakthrough Pain Assessment Questionnaire-Self Report (BTPAQ-SR) for Typically Developing Children and Young People (8-25 yrs) with Life-Limiting and Life-Threatening Conditions: An International e-Delphi Study of Expert Healthcare Professionals

建立针对典型发展儿童和青少年(8-25岁)的终末期和危及生命疾病突破性疼痛评估问卷-自我报告(BTPAQ-SR)的共识:一项针对专家医疗专业人员的国际电子德尔菲研究

2025-11-300
PRE
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
An innovative virtual fellowship leveraging global and regional mentorship to foster pediatric neuro-oncologists in low/middle-income countries

一项创新的虚拟 Fellowship 项目,利用全球和区域导师指导来培养低收入和中收入国家的儿科神经肿瘤学家

2025-01-010
OAAI
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL

复发/难治性小儿低级别神经胶质瘤 (PLGG) 中的II型RAF抑制剂TOVORAFENIB: 2期FIREFLY-1试验中生长速度的可逆降低

2024-06-180
OAAI
DEVELOPMENT OF THE ST. JUDE GLOBAL VIRTUAL PEDIATRIC NEURO-ONCOLOGY FELLOWSHIP (VPNOF): INCREASING PEDIATRIC NEURO-ONCOLOGY CAPACITY IN LOW- AND MIDDLE- INCOME COUNTRIES (LMIC)
2024-06-180
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2024-03-111
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

复发/难治性小儿低级别神经胶质瘤的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验

2023-11-1740
OAAI
CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOWGRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

泛RAF抑制剂TOVORAFENIB在2期FIREFLY-1 (PNOC026) 研究的注册儿科低级别神经胶质瘤组中的临床活性

2023-06-122
OAAI
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

分子表征定义了第4组髓母细胞瘤中临床可操作的异质性,并改善了疾病风险分层

2023-04-044
OAAI